Therapeutics for COVID-19 and post COVID-19 complications: An update

Debdoot Basu¹, Vivek P. Chavda², Anita A. Mehta¹,*

¹ Department of Pharmacology, L.M. College of Pharmacy, Navrangpura, Ahmedabad, 380009, Gujarat, India
² Department of Pharmacology, L.M. College of Pharmacy, Navrangpura, Ahmedabad, 380009, Gujarat, India

ABSTRACT

Since its inception in late December 2020 in China, novel coronavirus has affected the global socio-economic aspect. Currently, the world is seeking safe and effective treatment measures against COVID-19 to eradicate it. Many established drug molecules are tested against SARS-CoV-2 as a part of drug repurposing where some are proved effective for symptomatic relief while some are ineffective. Drug repurposing is a practical strategy for rapidly developing antiviral agents. Many drugs are presently being repurposed utilizing basic understanding of disease pathogenesis and drug pharmacodynamics, as well as computational methods. In the present situation, drug repurposing could be viewed as a new treatment option for COVID-19. Several new drug molecules and biologics are engineered against SARS-CoV-2 and are under different stages of clinical development. A few biologics drug products are approved by USFDA for emergency use in the covid management. Due to continuous mutation, many of the approved vaccines are not much efficacious to render the individual immune against opportunistic infection of SARS-CoV-2 mutants. Hence, there is a strong need for the cogent therapeutic agent for covid management. In this review, a consolidated summary of the therapeutic developments against SARS-CoV-2 are depicted along with an overview of effective management of post COVID-19 complications.

1. Introduction

Coronavirus disease 2019 (COVID-19), which has begun in Wuhan city of China, has already marked its presence globally with reports of reinfections due to endemics caused by the viral mutations (Indari et al., 2021; Tillet et al., 2021). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19 (Chavda et al., 2021; Indari et al., 2021). The cell receptor neuropilin-1 was discovered to be involved in SARS-CoV-2 entrance (Indari et al., 2021). Based on clinical symptoms, COVID-19 is classified as mild, moderate, or severe (Smail et al., 2021). Angiotensin-converting enzyme 2 (ACE-2) is the fusion receptor responsible for the attachment of the SARS-CoV-2 with the host (Chavda et al., 2021; Zhou et al., 2020). ACE-2 receptor is found in the lungs, heart, kidney, intestine, and endothelium, indicating that viruses can attach to a wide range of organs (Chavda et al., 2021f; Hadiziahe, 2021). Increased levels of proinflammatory cytokines like interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), IL-1, interferon-γ-inducible protein (IP10) and chemokines are observed, while decreased levels of cytotoxic T-lymphocytes (CTLs), helper (Th) cells, interferon γ (IFNγ) expressing (Th) cells characterize SARS-CoV-2 that corresponds to cytokine storm (Chavda et al., 2021b; Smail et al., 2021). This condition of hyperinflammation causes oxidative stress, which damages endothelial and alveolar cells in the lungs. Damage to these cells compromises the pulmonary membrane, resulting in vascular leakage, increased lung edema, and acute respiratory distress syndrome (ARDS) (Smail et al., 2021). Chemokines attract macrophages and neutrophils to the lungs, resulting in acute lung injury (ALI), disseminated intravascular coagulation, multiple organ dysfunction, and death in patients with severe COVID-19 (Smail et al., 2021) (see Figs. 1 and 2).

Viruses constantly change through mutation (CDC, 2021; Chavda et al., 2021a). Many variants of SARS-CoV-2 have been detected all around the world during this epidemic (Chavda et al., 2021a). According to WHO, the classification of novel coronavirus variants are variants of concern (VOC) and variants of interest (VOI) (World Health Organization, 2021a,b). According to CDC, VOC is defined as “a variant for which there is evidence of an increase in transmissibility, more severe disease (e.g., increased hospitalizations or deaths), a significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures”, and VOI is defined as “A variant with specific genetic markers that have been associated with changes to receptor binding, reduced neutralization by antibodies generated against previous infection or vaccination, reduced efficacy of treatments, potential
diagnostic impact, or predicted increase in transmissibility or disease severity” (CDC, 2021). In the current situation, the increased amount of transmissibility of SARS-CoV-2 occurs because of these variants (Chavda et al., 2021e). Most SARS-CoV-2 variants have a mutation in the spike protein of the virus (Chavda et al., 2021c, 2021d; World Health Organization, 2021a,b). On Aug 14, 2021,139 countries have reported VOCs like VOC 202012/01 (first found in the UK), 87 countries have reported VOC 501Y.V2 (first found in South Africa), and 54 countries have reported VOC.P1 (first found in Brazil) (World Health Organization, 2021a, b). VOIs like 1.617 (first found in India), B.1.616 (first found in France), B.1.526 with E484K or S477N (first found in the US), and P.3 (first found in Philippines and Japan) is spreading globally (World Health Organization, 2021a,b). On November 24, 2021, the World Health Organization received notification of a new variant of SARS-CoV-2, B.1.1.529 detected in South Africa on November 14, 2021. On November 26, 2021, World Health Organization (WHO) designated the B.1.1.529 (Omicron) as a Variant of Concern (VOC) (NCIRD, 2021).

There are many evolving vaccines against SARS-CoV-2 that are administered to date but the effectiveness of vaccines against these new variants is not evident and is the topic of current research interest. Hence, there is always a need for a new therapeutic tool to target SARS-CoV-2 effectively to curb the spread of SARS-CoV-2. Due to public health emergency, there are many ongoing clinical researches on a therapeutic option that includes repurposing drugs, monoclonal antibodies etc. This review will discuss the wide range of medications that can potentially be used in the treatment of COVID-19.

## 2. Statistics for the pandemic horizon

Up to December 22, 2021, there have been 27 million confirmed positive COVID-19 cases and 5.3 million fatalities are being reported of COVID-19 by WHO (World Health Organization (WHO), 2021). A total of 838 million doses of vaccines have been administered for COVID-19 as of December 19, 2021 (World Health Organization (WHO), 2021a,b). Reports from WHO revealed that the positive cases of COVID-19 are increasing many folds week by week all over the world. The countries with the most cases were United States of America (48413265 cases) India (34,615,757 cases), Brazil (22,105,872 cases), United Kingdom (10,329,078 cases), and Russian Federation (9,737,037 cases) (World Health Organization, 2021a,b) (Fig. 1).

It is estimated that around 70% of the world’s population will need to gain immunity against SARS-CoV-2 to acquire herd immunity (Dhar...
Chowdhury and Oommen, 2020). For achieving herd immunity against COVID-19, researchers around the world constantly developing vaccines. Most people who got fully vaccinated with both doses were United Arab Emirates (90.3%) followed by Singapore (87.88%), Portugal (86.2%), Malta (86%) (Ourworldindata.org, 2020). In WHO, research is going on for finding candidates for developing better vaccines against COVID-19 (Dhar Chowdhury and Oommen, 2020).

3. Drug repurposing for COVID-19

The process of identifying new targets for existing medications is known as drug repurposing, and it is regarded as a cost-effective and efficient method (Jang et al., 2021; Singh et al., 2020). It is estimated that 75% of already available drugs may be repurposed to treat a variety of diseases (Singh et al., 2020). Outbreaks of SARS-CoV-2, present particular obstacles to clinicians in terms of selecting suitable pharmacological drugs in a clinical setting with little time for novel drug discovery (Fig. 2) (Bakowski et al., 2021). Repurposing of existing medicines for the treatment of multiple diseases has recently become a common technique since it utilizes risk-free compounds with familiar pharmacodynamic, preclinical, and pharmacokinetic profiles that can go straight through the late phase of clinical trials, allowing the development of drug process effectively low-price and faster (Wang and Guan, 2021). Therefore, the quest for successful COVID-19 therapeutic drugs are critical and immediate (Fig. 3).

3.1. Potential drugs that act through SARS-CoV-2 related targets (genomic) in ongoing clinical trials

3.1.1. Remdesivir

Remdesivir has a wide range of antiviral activities against coronaviruses (Singh et al., 2020; Smith et al., 2020). Previously, remdesivir was used as an investigational drug for the ebola virus (Singh et al., 2020). The possible mechanism of action by which remdesivir may help to treat COVID-19 is by inhibition of viral replication. The enzyme RNA-dependent RNA polymerases (RdRps) are needed for SARS-CoV-2 replication. Remdesivir is a mono-phosphoramidite prodrug of remdesivir-triphosphate (RDV-TP), an adenosine analog that inhibits RdRps (Singh et al., 2020; Smith et al., 2020). Adenosine-triphosphate competes with remdesivir-TP for insertion into embryonic viral RNA chains. Since RDV-TP does not induce immediate chain termination, it terminates RNA synthesis until it is integrated into viral RNA (Singh et al., 2020; Smith et al., 2020). Several clinical trials are going on all over the world for its efficacy against COVID-19 (Table 1). A clinical study in the US reported that remdesivir improved clinical conditions of severe COVID-19 patients (Hoek et al., 2021; Wang et al., 2020). When patients with severe COVID-19 were given remdesivir, symptomatic improvement was seen in a clinical study (Ader et al., 2021; Buckland et al., 2020). Currently, remdesivir is the only USFDA approved repurposed drug for severe COVID-19 conditions (Authorization, 2021).

3.1.2. Favipiravir

Favipiravir is approved in Japan for influenza viruses (Singh et al., 2020). Favipiravir is a prodrug of purine nucleotide which converts into active form favipiravir-ribonanosyl triphosphate (favipiravir-RTP) within the tissue, works by inhibiting the SARS-CoV-2’s RdRp enzyme. It allows favipiravir to be easily inserted into viral RNA thus sparing human DNA which results in virucidal activity (Agrawal et al., 2020). In Wuhan, where COVID-19 started, favipiravir was initially used to treat COVID-19 (Agrawal et al., 2020). In China, a clinical study reported faster clearance of viral load and amelioration in lung CT scans when patients with COVID-19 were administered with favipiravir as compared with other treatment arms (Agrawal et al., 2020). An observational study conducted in Japan reported faster recovery from favipiravir in patients with mild and moderate COVID-19 (Shinkai et al., 2021). In India, DCGI approved favipiravir in mild and moderate COVID-19 patients. Emergency use of

Fig. 2. The overview diagram of SARS-CoV-2 invasion and the response of host immune system along with targeted drugs for different viral replication steps. (Adopted under CC BY 4.0 license from (Zhou et al., 2021).
 Favipiravir is approved in many countries which includes Russia, Japan, Italy, Moldova, Bangladesh, Turkey, Egypt, Ukraine, Uzbekistan, and Kazakhstan (Agrawal et al., 2020). Detailed ongoing trials are summarized in Table 1.

3.1.3. Molnupiravir

Molnupiravir, the prodrug of ribonucleoside analog of β-D-N4-hydroxycytidine (Vicenti et al., 2021). It has been shown to prevent the replication of a variety of viruses with low cytotoxicity and a high degree of resistance. When the active form of a drug gets incorporated in the virus instead of uracil or cytosine during RNA synthesis which causes G to A and C to U transformations in a dose-dependent manner resulting in deadly mutagenesis through the entire genome of many viruses (Fischer et al., 2021; Vicenti et al., 2021). This possible mechanism of action of molnupiravir may also prevent viral replication via inhibiting SARS-CoV-2-RdRp in a host cell (Vicenti et al., 2021). The efficacy of molnupiravir was proved against influenza and various coronaviruses (Kabinger et al., 2021). A clinical study is going for the efficacy of molnupiravir against COVID-19 (Table 1).

Fig. 3. Repurposed drugs for COVID-19 and their mechanism of action.
### Table 1

**Drugs repurposing for COVID-19 under clinical development.**

| The phase of clinical trial | Trade Name/Generic Name | Medication Class | Innovator | The possible mechanism in COVID-19 | Dosage form | Registered clinical trial no |
|-----------------------------|-------------------------|------------------|-----------|-----------------------------------|-------------|-------------------------------|
| Phase 4                     | Carragelose®            | Antiviral        | Marinomed Biotech AG | It acts as a defensive physical shield on the oral and nasal mucosa for virus entry to the host cell. | Nasal spray | NCT04590365, NCT04681001, NCT04521322, NCT04793984 |
| Phase 3/4                   | Eliquis (Apixaban)      | Anticoagulant    | NHLBI     | Adjunctive/Supportive therapy, to mitigate immunothrombosis in COVID-19. Apixaban, a thromboxane A2 receptor antagonist will inhibit COX2 stimulated TxA2 signaling, as COX2 is upregulated by COVID 19. | Oral        | NCT04498273, NCT04650087, NCT04601940, NCT04746339, NCT04512079 |
| Phase 2/3/4                 | Vascepa (icosapent ethyl) | Lipid-lowering agent | Amarin Corporation | Anti-inflammatory effects in COVID-19 | Oral | NCT04412018, NCT04460651, NCT04505098, NCT04520079 |
| Phase 3                     | Regkirona (regdanvimab, CT-P59) | Monoclonal antibody | Genetrix | Neutralize SARS-CoV-2 virus and several variants like mutated G-variant strain (D614G) by acting on viral RBD. | L.V. | NCT04625725, NCT04625972, NCT04723994, NCT04518410, NCT04501978 |
| Phase 3                     | AZD7442                  | Monoclonal antibody | Asta Zeneca; Vanderbilt University Medical Center | Targets the viral S protein | L.V. | NCT04583956, NCT04362813, NCT04365153 |
| Phase 3                     | Lenalimumab              | Monoclonal antibody | Humagen; Catalent Novartis | Antagonize GM-CSF signaling in COVID-19. | L.V. | NCT04583956, NCT04362813, NCT04365153 |
| Phase 3                     | Losmapimod               | Mitogen-activated protein kinase (MAPK) inhibitor | Fulcrum Therapeutics | DUX4 protein inhibitor, p38 mitogen-activated protein kinase inhibitors reduces inflammatory biomarkers such as C-reactive protein and IL-6 in COVID-19. | Oral | NCT04511819 |
| Phase 3                     | Actemra (tocilizumab)    | IL-6 inhibitors  | Roche     | Anti IL-6 Receptor mAb | L.V. | NCT04320615, NCT04372186, NCT04409262, NCT04381936 |
| Phase 3                     | Bucillamine              | Antirheumatic agent | Revive Therapeutics Ltd. | Prevent acute lung injury, immunomodulator in COVID-19 | Oral | NCT04504734, NCT04421508 |
| Phase 3                     | INOpulse                 | Nitric oxide     | Bellerophon Therapeutics | iNOS hinders the coronavirus replication via intermediate peroxynitrite. | Inhaled | NCT04548305, NCT02517489 |
| Phase 3                     | Hydrocortisone           | Glucocorticoid   | Various   | Inhibition of proinflammatory transcription factors in severe COVID-19 | Oral | NCT04486313, NCT04359680, NCT04342248, NCT04497987, NCT04634409, NCT04518410, NCT04501978, NCT04411628, NCT04343651, NCT04347229, NCT04593940 |
| Phase 3                     | NT-300 (nitazoxanide extended release) | Antiviral | Romark Laboratories L.C. | Inhibits SARS-CoV-2 effect on interferon pathway; upregulates innate immunity and interferon pathway | Oral | NCT04583956, NCT04362813, NCT04365153, NCT04497987, NCT04634409, NCT04518410, NCT04501978, NCT04411628, NCT04343651, NCT04347229, NCT04593940 |
| Phase 2/3                   | Bamlanivimab + etesevimab | Monoclonal antibodies | Lilly; Junshi Biosciences | Acts on S Protein and prevents viral entry in the host. | L.V. | NCT04320615, NCT04372186, NCT04409262, NCT04381936 |
| Phase 2/3                   | Leronlimab (PRO 140)     | Monoclonal antibody | CytoDyn | CCR5 antagonist which causes the downstream release of proinflammatory cytokines | L.V. | NCT04343651, NCT04347229, NCT04593940 |
| Phase 2/3                   | Remicade (infliximab)    | Monoclonal antibody | Janssen | Tumor necrosis factor inhibitor for cytokine release syndrome linked with COVID-19 | L.V. | NCT04343651, NCT04347229, NCT04593940 |
| Phase2/3                    | Veklury (Remdesivir)     | Antiviral        | Gilead Sciences | Inhibits RNA polymerases (RdRps) | L.V. | NCT04343651, NCT04347229, NCT04593940 |
| Phase 2/3                   | SNG001                   | Antiviral        | Synairgen | Interferon-beta-1a proteins which have antiviral properties | L.V. | NCT04385095, NCT04732949, NCT04518410 |

(continued on next page)
| Phase of clinical trial | Trade Name/Generic Name | Medication Class | Innovator | The possible mechanism in COVID-19 | Dosage form | Registered clinical trial no |
|------------------------|------------------------|------------------|-----------|-----------------------------------|------------|-----------------------------|
| Phase 2/3              | Niclocide (niclosamide), UNI91103 | Anthelmintic | Neuro Rx, Pharma; UNION therapeutics | It inhibits SKP2 (S-Phase kinase-associated protein-2) | Oral | NCT04603924, NCT04436458, NCT0479173, NCT04372082 |
| Phase 2/3              | Ivermectin             | Antihelmintic    | Various | It is a nuclear transport inhibitor mediated by the importinα/β-1 heterodimer | Oral | NCT04529525, NCT0438850, NCT04431466, NCT04703205, NCT04360096, NCT04843761, NCT04511697, NCT04453839, NCT04536350, NCT04488081 |
| Phase 2/3              | Zyesami (aviptadil, RLF-100) | Synthetic human vasoactive intestinal peptide | Neuro Rx, Relief Therapeutics | Vasoactive intestinal peptide (VIP) is highly localized in the lungs and prevents apoptosis and caspase-3 activation in the lungs, as well as halts the manufacturing of IL6 and TNF alpha and reversing the CD4/CD8 ratio. | Oral | NCT044575107, NCT04532931, NCT0701606, NCT04695197 |
| Phase 2/3              | Dexamethasone           | Glucocorticoid   | Various | Decreases the inflammation linked with cytokine release syndrome | Oral | NCT04475107, NCT04532931, NCT04640168, NCT04327401, NCT04701606, NCT0448081 |
| Phase 2/3              | Pyramax (artesunate/pyronaridine) | Antimalarial     | Shin Poong Pharmaceutical Co., Ltd | Antiviral activity is depicted through the TLR4 inflammatory signaling pathway | Oral | NCT04784897, NCT04351243, NCT04351236, NCT04469967 |
| Phase 1/3              | CPI-006                 | Immunomodulatory antibody | Corvus Pharmaceuticals, Inc. | Anti-CD73 antibody; inhibits viral replication and suppressed IL-6, IL-17A, IL-17F, and vascular endothelial growth factors in cell culture. | I.V. | NCT0446395, NCT04734873 |
| Phase 2                | Brilacidin (PMX-30063) | Host defense protein mimetic | Innovation Pharmaceuticals | Binds to the spike proteins of SARS-CoV-2 and prevents viral entry in a host cell | I.V. | NCT04784897, NCT04351243, NCT04351236, NCT04469967 |
| Phase 2                | Gimsilumab              | Monoclonal antibody | Roivant Sciences | GM-CSF antagonist | I.V. | NCT04784897, NCT04351243, NCT04351236, NCT04469967 |
| Phase 2                | APN01                   | AntitNF          | Apteon Biologics | Recombinant human ACE-2 enzyme that blocks ACE2 receptor, prevents SARS-CoV-2 entry to host cell | I.V. | NCT04784897, NCT04351243, NCT04351236, NCT04469967 |
| Phase 2/2              | Humira (adalimumab)    | Anti-TNF         | University of Oxford, Pharm-Olam | Anti-tumor necrosis inhibitor in COVID-19 | I.V. | NCT04705844, NCT04358406, NCT04401423 |
| Phase 2                | AT-527                  | Antiviral        | Atea Pharmaceuticals Inc. | Inhibit viral replication by interfering with viral RNA polymerase | Oral | NCT04396106, NCT04440007, NCT04528667, NCT04433456 |
| Phase 2                | PTC299                  | Dihydroorotate dehydrogenase (DHODH) inhibitor | PTC | DHODH inhibitor; inhibits viral replication and suppressed IL-6, IL-17A, IL-17F, and vascular endothelial growth factors in cell culture. | Oral | NCT0439071 |
| Phase 1,2              | PF-0146                | VIP receptor agonist | PhaseBio | VIP agonist possesses control of cell activation and differentiation, down-regulation of proinflammatory cytokines especially IL-10 in SARS-CoV-2 | I.V. | NCT04784897, NCT04351243, NCT04351236, NCT04469967 |
| Phase 2                | BLD-2660                | Small molecule protein inhibitor | Blade Therapeutics | Small molecule inhibitor of calpain for treatment in pneumonia associated with COVID-19 | Oral | NCT04334460, NCT04334460, NCT04334460, NCT04334460 |
| Phase 2                | Rhu-pGSN (gelsolin)    | Recombinant human plasma | BioAegis Therapeutics | Suppress cytokine release syndrome associated with COVID-19 | I.V. | NCT04358406, NCT04401423 |
| Phase 2                | TXA127                  | Angiotensin (1-7) peptide | Constant Therapeutics | Mas receptor agonist which has demonstrated efficacy in reducing inflammation, stabilizing endothelial and epithelial barrier and reducing fibrosis in lungs | I.V. | NCT04401423 |
| Phase 2                | LAM-002A (apillimonomidemyleate) | Interleukin inhibitor | AI Therapeutics, Inc. | Inhibits lipid kinase PIKfyve | Oral | NCT04446377 |
| Phase 2                | AdMScA                  | Autologous adipose-derived stem cells | Celltex Therapeutics | Effectively treating pneumonia associated with COVID-19 | Oral | NCT04428801 |
| Phase 1                | PF-07321332             | Antiviral        | Pfizer | Pro tease inhibitor that blocks 3-CL pro in SARS-CoV-2 | Oral | NCT04756531, NCT04834856 |
| Phase 1                | Enoxibep (MP0420)      | Antiviral        | Molecular Partners; Novartis | Bind to the RBD of viral S protein at three distinct locations to prevent viral entry into cells. A prodrug which is a potent inhibitor in vitro of the coronavirus family 3CL pro, especially targets human host protease. | Oral | NCT04535167, NCT04460105 |
| Phase 1                | PB-00835321 (PF-07304814) | Monoclonal antibody | Takeda (Shire) | Lanadelumab blocks the activation of bradykinin which has been theorized to be responsible for vascular dilation, vascular permeability, and hypotension when bradykinin levels increase during COVID-19 | I.V. | NCT04460105 |
| Phase 1                | DNL758 (SAR443122)     | RIPK1 inhibitor | Sanofi; Denali Therapeutics | Reduce excessive inflammation associated with severe cases of COVID-19 | Oral | NCT04469621 |
Clinical trials are underway regarding the efficacy of AT-527 (Table 1).

3.1.7. PF-07321332

PF-07321332 is a double prodrug of a guanosine nucleotide analog that has shown effective in vitro and in vivo activity against hepatitis C virus (HCV) by specifically inhibiting RdRp (Good et al., 2021). Good et al. found that in an in vitro study, where AT-527 shows potent activity for COVID-19. Clinical trials are underway regarding the efficacy of AT-527 (Table 1).
can aggravate lymphopenia by destroying T cells directly through TNF/TNFRI signaling. T cell dysfunction is an essential but underappreciated target for immunomodulatory involvements. So, anti-TNF targets may be encouraging to use in cytokine storm of COVID-19 but its effect can be seen only in severe COVID-19 patients (Stallmach et al., 2020). The clinical trial is ongoing for infliximab against SARS-CoV-2 (Table 1).

3.3.5. Artesunate/pyronaridine

The antimalarial drug combination artemesunate and pyronaridine have had a wide range of the antiviral spectrum (Nair et al., 2021). Artesunate's antiviral effects against DNA viruses have been well documented, and clinical trial is ongoing for in

3.3.6. Gimsilumab

Gimsilumab, a mAb used in ankylosing spondylitis (Saha et al., 2020). Granulocyte-macrophage colony-stimulating factor (GM-CSF), an important myelopoietic growth factor, flashed a lot of attention as a potential pharmacological drug that may use in COVID-19 (Lang et al., 2020). Gimsilumab as anti-GM-CSF may work in mitigating cytokine storm in COVID-19. In the cohort study, encouraging results are shown by anti-GM-CSF monoclonal antibodies against COVID-19 (Lang et al., 2020).

3.3.7. Miscellaneous drugs with a novel mechanism against SARS-CoV-2

1) Apilimod: It may mitigate proinflammatory cytokines by inhibition of lipid kinase PI3Kγ (phosphoinositide kinase for position 5 containing an FYVE finger domain) in cellular regulation (Riva et al., 2020).

2) Pemziviptadi (PB1046): Vasoactive intestinal peptide agonist that controls cell activation and differentiation, as well as the down-regulation of proinflammatory cytokines and reactive oxygen species and the promotion of the anti-inflammatory cytokine IL-10 (Ngo et al., 2021).

3) BLD-2660: Small molecule inhibitor of calpain for treatment in pneumonia caused by COVID-19 via decreasing of proinflammatory cytokines (Ayaydin et al., 2021).

4) Abivertinib: Tyrosine kinase inhibitor, which specifically binds to Bruton's tyrosine kinase (BTK) receptors which causes prevention of phosphorylation of the receptor that leads to inhibition of proinflammatory cytokines like IL-6, IL-β, and TNF-α in severe COVID-19 (Jade et al., 2021).

5) Lanadelumab: Increased activity of bradykinin also leads to an increase in the inflammation in the lungs which can lead to acute lung inflammation (Colarusso et al., 2020). Lanadelumab, an inhibitor of bradykinin can be a potential therapy by mitigating proinflammatory cytokines (Adesanya et al., 2021).

6) DN1758: Inhibition of Receptor-interacting serine/threonine kinase 1 which causes inhibition of proinflammatory cytokines in COVID-19 (Bime et al., 2021).

7) Ensivibep and MP0423: Trade name under DARPin® (Designed ankyrin repeat proteins), antivirals, which have shown to be novel potent antiSARS-CoV-2 and also showed effectiveness in mutant strains of SARS-CoV-2 (Rothenberger et al., 2021). Previously DARPin® was used in oncological studies (Stumpf et al., 2020). Rothenburger et al. revealed the novel mechanism of action of ensivibep against SARS-CoV-2 as “the viral inhibition mode of ensivibep is based on three distinct DARPin® domains targeting the RBD while MP0423 has three DARPin® domains directed to three different domains of the spike protein: the RBD, the N Terminal Domain (NTD) and the S2 domain. The tripartite binding and RBD-independent neutralization mechanism allow the MP0423 molecule to lose binding to any of its domains while maintaining a high neutralizing potency” (Rothenberger et al., 2021). Phase 1 trials are ongoing for this novel molecule against SARS-CoV-2 (Table 1).

8) 2-deoxy-D-glucose (2-DG): The host cells have been reported to perform metabolic reprogramming after SARS-CoV-2 entry to satisfy the increased demand for nutrients and energy for viral replication, where 2-DG, a glucose antimetabolite, might be a promising therapeutic option since it works as a dual inhibitor of glycolysis and glycosylation (Balkrishna et al., 2020).

4. USFDA approved therapeutics for COVID-19

USFDA follows a systematic approach to combat COVID-19. To date, US-FDA approved only remdesivir drugs to be used in hospitalized COVID-19 patients (Authorization, 2021). US-FDA granted emergency use authorization (EUA) to neutralizing antibodies (bamlanivimab + etesevimab, and casirivimab/imdevimab), antiviral combination therapy of remdesivir + baricitinib and COVID-19 convalescent plasma (Taylor et al., 2021). The BLAZE-1 trial (NCT04427501) investigated the combination of bamlanivimab and etelevmab in COVID-19 patients who were ambulatory comparing with single monotherapy of bamlanivimab. The combination of bamlanivimab/etelevmab was accompanied by a significant decrease in viral load compared to placebo. According to virological data from 577 patients, whereas bamlanivimab monotherapy did not lead to significant decrease in the viral load. The monoclonal antibody combination was also found to decrease the number of hospitalizations and deaths in 1035 patients when compared to placebo. This result led to grant EUA to monoclonal antibody combination (bamlanivimab and etesevimab) in mild to moderate COVID-19 patients by USFDA (Hurt and Wheatley, 2021). In a phase 1/2/3 trial (NCT04425629) which is happening in many countries, casirivimab and imdevimab are being tested as a cocktail in ambulatory patients. The results of a phase 3 analysis (N = 4567) of patients with serious COVID-19 comparing 1200 mg or 2400 mg casirivimab/imdevimab to placebo have been published. As compared to placebo, the casirivimab/imdevimab combination significantly decreased the chance of mortality or hospitalization by 70% and 71% in 1200 mg dose arm and 2400 mg dose arm respectively (Hurt and Wheatley, 2021). The median period of symptoms reduced by 4 days was shown by antibody cocktail therapy when compared to placebo. When compared to placebo, interim results from the first 275 patients (phase 1/2 portion) revealed that the casirivimab/imdevimab combination showed virological effectiveness, resulting in an overall decrease (Hurt and Wheatley, 2021). These findings from the trial led to grant EUA by USFDA for the use in mild to moderate COVID-19 patients in the ambulatory setting. Convalescent plasma carrying antibodies of SARS-CoV-2 given to the patients with severe COVID-19 is the treatment approach whose observational data are very encouraging but clinical trials did not prove the evidence (Simovich et al., 2021). Many countries grant emergency authorization to convalescent plasma in severe COVID-19 patients based on observational data (Simovich et al., 2021). Clinical trial data (NCT04401579) of antiviral drugs (Baricitinib with remdesivir) compared to remdesivir alone showed that in COVID-19 patients who were undergoing high-flow oxygen or noninvasive ventilation, baricitinib plus remdesivir was advantageous to remdesivir alone in minimizing improvement time and fast-tracking patient’s progress (Kalil et al., 2021). The combination was also linked to a lower risk of severe side effects when compared to remdesivir alone in a study of 1033 patients (Kalil et al., 2021). These outcomes led to the grant of EUA by FDA in hospitalized COVID-19 patients (Authorization, 2021). ACTT-1 trial showed that Remdesivir was shown to be significant improvement than placebo group in the hospitalized patients and also had lower chance of respiratory tract infection (Beigel et al., 2020). Furthermore, US-FDA also approved supportive/adjuvant therapy in COVID-19 which includes propofol-lipuro 1%, “REGICOF replacement solution that contains citrate for regional citrate anticoagulation (RCA) of the extracorporeal circuit, Fresenius medical, multifiltrate PRO system, and multiBic/multiPlus

D. Bima at el. 
Current Research in Pharmacology and Drug Discovery 3 (2022) 100086
5. Novel anti SARS-CoV-2 drugs under clinical development

Vaccines may be the effective means of providing COVID-19 immunity to the majority of people. However, specific novel anti-SARS-CoV-2 medications are anticipated to play a major role in protecting people who are unvaccinated or immunocompromised, as well as at periods when vaccinations fail to protect against circulating SARS-CoV-2 variant (Chavda et al., 2021). Few novel anti-SARS-CoV-2 molecules are already in clinical trials to target the SARS-CoV-2 virus. Monoclonal antibodies against SARS-CoV-2 are of great interest during this pandemic. Monoclonal antibodies target the spike protein of SARS-CoV-2 to neutralize it (Hurt and Wheatley, 2021). However, the concern is that the emerging clonal antibodies target the spike protein of SARS-CoV-2 to neutralize it against SARS-CoV-2 are of great interest during this pandemic. Monoclonal antibodies in clinical trials to target the SARS-CoV-2 virus. Monoclonal antibodies (Chavda et al., 2021f). Few novel anti-SARS-CoV-2 molecules are already vaccinations fail to protect against circulating SARS-CoV-2 variant. US FDA already granted EUA for casirivimab and imdevimab as activity of imdevimab is unaffected by resistance to bamlanivimab and etesevimab respectively. Inhibition of variants like B.1.351 have spike substitution of E484K and K417N that is resistant to bamlanivimab and etesevimab respectively. Inhibition of B.1.351 by only 5 to 20-fold was succeeded by cocktail therapy of casirivimab/imdevimab, an artificial cocktail antibody against the spike proteins of SARS-CoV-2 (Authorization, 2021). Success of these novel molecules in clinical studies may certainly help in curb the spread of pandemic. Novel anti SARS-CoV-2 molecules are summarized in Table 3.

6. Coronavirus treatment acceleration program (CTAP)

"Coronavirus Treatment Acceleration Program" (CTAP), developed by the USFDA, is a distinct emergency program for potential coronavirus treatments (Manager et al., 2021). The program employs any available technique to get novel therapies to patients as soon as possible while still determining whether they are beneficial or detrimental. The FDA continues to fund clinical trials that are evaluating novel COVID drugs to collect useful information on their safety and efficacy (Manager et al., 2021; Rome and Avorn, 2020). As of Aug 4, 2021, under the CTAP program, more than 600 drugs are in the planning stages of drug development programs, 10 number COVID-19 drugs under emergency use authorization, examines more than 400 trials and 1 treatment drug is currently approved by FDA. Furthermore, under CTAP, more than 50 antiviral treatments, more than 40 cells, and gene therapies, and more than 130 immunomodulators, and more than 50 neutralizing antibodies, more than 110 therapeutics from other pharmacological categories are being studied for COVID-19 treatment. More than 100 and 330 therapeutics are in early-stage (phase 0,1,1/2) and late-stage (phase 2,2/3,3,4) respectively for COVID-19 treatment (Chen et al., 2020; Manager et al., 2021).

Table 2

| Name | Class of drug | Innovator | The possible mechanism in COVID-19 | Dosage form | USFDA Authorized use | Reference |
|------|---------------|-----------|-----------------------------------|-------------|----------------------|-----------|
| Bamlanivimab + Etesevimab | Monoclonal antibodies | Lilly, Junshi Biosciences | Binds to the spike proteins of SARS-CoV-2 and prevents viral entry in a host cell. | I.V. | “For the treatment of mild to moderate COVID-19 in adult and pediatric patients” | Katz (2021) |
| Casirivimab/imdevimab (REGN-COV2) | Monoclonal antibodies | Regeneron | Binds to the spike proteins of SARS-CoV-2 and prevents viral entry in a host cell. | I.V. | “Treatment to mild to moderate COVID-19 in adult and pediatric patients (12 years of age and older weighing at least 40 kg)” | Weinrich et al. (2020) |
| Baricitinib (Olumiant) in combination with remdesivir (Veklury) | Antiviral drug | Eli Lilly | Targets two distinct epitopes on RBD. JAK (Janus kinase) and RNA polymerases (RdRps) inhibitor | Orally, I.V. | “In hospitalized adults and pediatric patients of 2 years of age and older who require supplementary oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation, for the treatment of suspected or confirmed COVID-19”. | Kalil et al. (2020) |
| Remdesivir (Veklury) | Antiviral drug | Gilead Sciences | Inhibits RNA polymerases (RdRps) | I.V. | FDA approved remdesivir for use in COVID-19 hospitalized patients (12 years of age and older and weighing at least 40 kg) | Beigel et al. (2020) |
| Convalescent plasma | Plasma | Bratcher Bowman | Antibodies of COVID-19 | | “For the treatment of hospitalized patients with COVID-19” | |

Table 3

| The phase of clinical trial | Trade Name/Generic Name | Medication Class | Innovator | The possible mechanism in COVID-19 | Dosage form | Registered clinical trial no |
|---------------------------|-------------------------|------------------|-----------|-----------------------------------|-------------|-----------------------------|
| Phase 2/3                 | SAB-185                 | Polyclonal antibody | SAB Biotherapeutics | Anti-SARS-CoV-2 Human immunoglobulin G | I.V. | NCT04469179, NCT04518410 |
| Phase 2/3                 | CI35-LS/CI44-LS         | Monoclonal antibodies | The Rockefeller University/Bristol Myers Squibb | Targets two distinct epitopes on RBD | I.V. | NCT04700163, NCT04518410 |
| Phase 1/2/3               | Casirivimab/imdevimab (REGN-COV2) | Antibody cocktail | Regeneron | Target the spike protein of SARS-CoV-2, hindered infectivity, and prevented the emergence of viral resistant mutants | I.V. | NCT04425629, NCT04426695, NCT04519437, NCT04452318 |
| Phase 1b/2a/2/3           | VIR-7831/VIR-7832 (GSK4182136/GSK4182137) | Monoclonal Antibody | Vir Biotechnology, Inc.; GSK | Binds to the spike proteins of SARS-CoV-2 and prevents viral entry in a host cell. | I.V. | NCT04540606, NCT04634490 |
| Phase 1                   | ETZEVIR(C10/12G)        | Monoclonal antibody | Lilly; Junshi Biosciences | Binds to the spike proteins of SARS-CoV-2 and prevents viral entry in a host cell. | I.V. | NCT04427501, NCT04497987, NCT04634409 |
| Phase 1                   | COVI-AMG/COVI-DROPS (STI-2020) | Monoclonal antibody | Sorrento Therapeutics | Binds to the spike proteins of SARS-CoV-2 and prevents viral entry in a host cell. | I.V. | NCT04586697 |
| Phase 1                   | COVI-GUARD (STI-1499)  | Monoclonal antibody | Sorrento Therapeutics | Neutralizing antibody that binds to the S1 subunit of the spike protein in SARS-CoV-2. | I.V. | NCT04454398 |
7. Critical evaluation of drugs used in treatment of COVID-19

Despite having strong in vitro efficacy against SARS-CoV-2 and clinical results from other human coronaviruses such as SARS and MERS, the repurposed drugs have failed to show efficacy in clinical studies (Indari et al., 2021; Martinez, 2021). Various clinical trials of repurposed drugs are reported and showed no beneficial effect in COVID-19 (Martinez, 2021). Some major repurposed drugs used from the beginning of the outbreak of COVID-19 were hydroxychloroquine and chloroquine, favipiravir, ribavirin, lopinavir-ritonavir, interferons (Martinez, 2021; Vandyck and Deval, 2021). Based on the data of observational study on few patients and micromolar concentrations in tissue culture, antimalarial drugs like hydroxychloroquine and chloroquine were used against SARS-COV-2 (Kamat and Kumari, 2021). However, large clinical studies have showed no benefit of hydroxychloroquine and/or chloroquine drugs against COVID-19 in reducing morbidity or mortality (Martinez, 2021). A prospective clinical trial showed that favipiravir failed to improve SARS-CoV-2 clearance in hospitalized patients (Doi et al., 2020). A large multicenter retrospective cohort study revealed that there is no clinical benefit of ribavirin/interferons in COVID-19 (Li et al., 2021). No clinical benefit was established when HIV-1 protease inhibitors like lopinavir-ritonavir was used against SARS-CoV-2 (Cao et al., 2020). Remdesivir, US-FDA approved drug for COVID-19 showed no benefit of mortality in clinical study reported by wang and colleagues (Wang et al., 2020b). Solidarity trial by WHO also revealed no effect of mortality, period of hospital stay and beginning of ventilation by remdesivir, hydroxychloroquine, lopinavir and interferons therapy in COVID-19 patients (WHO, 2020). However, clinical study in US reported that remdesivir improved clinical outcomes in severe COVID-19 patients (Singh et al., 2020). These conflicting results showed that strong evidence is lacking for remdesivir that is to be used in COVID-19. The clinical evidence of the use of ivermectin in COVID-19 is also limited (Mega, 2020). Immunomodulators like dexamethasone improved the mortality benefits among severe COVID-19 patients in hospitalized patients of COVID-19 (Martinez, 2021).

8. Post COVID-19 complications and its management

It is reasonable to expect that 80% of those who recovered from COVID-19 of a mildly symptomatic appearance will not have long-lasting consequences and will ultimately improve completely. Patients with a relatively serious symptomatic appearance that needed hospitalization but not artificial ventilation had no mid-term complications (Lai et al., 2020). Patients with serious symptomatic presentation who need artificial ventilation likely to experience long-term problems and delayed recovery aging(del Rio et al., 2020). Changes in the pathophysiology of SARS-CoV-2, inflammatory damage, and immunologic irregularities in COVID-19 are all potential pathways leading to post-COVID-19 complications. The various multiorgan system can be affected in severe COVID-19 survivors (Nalbandian et al., 2021) (Fig. 4).

8.1. Pulmonary conditions and their management after COVID-19

COVID-19 survivors have recorded a wide range of pulmonary symptoms, from dyspnea to complicated fibrotic lung injury and ventilator weaning (Nalbandian et al., 2021). The most prevalent chronic symptom outside acute COVID-19 is dyspnea, with 42–66 percent prevalence at 60–100 days follow-up, similar to the recovered patients from ARDS of different etiologies.

A tentative finding of an important radiological and symptomatic change in a sample of COVID-19 recovered patients shows that at post-COVID-19, corticosteroid treatment could be effective in a subset of patients (Myall et al., 2021). ARDS caused by severe COVID-19 and influenza A (H1N1) infection, lung transplantation was previously done for fibro proliferative lung disease (Nalbandian et al., 2021). Antifibrotic treatments are being tested in clinical trials to suppress pulmonary fibrosis after COVID-19 (Peter M George et al., 2020).

Fig. 4. Post COVID-19 complications involving different organ system. (Adopted under permission from (Zheng et al., 2021)).
8.2. Hematologic conditions and their management after COVID-19

The prevalence of venous thromboembolism (VTE) was reported in the 5% of patients recovered from COVID-19 (Nalbandian et al., 2021). While definitive proof is lacking, provided with sustained primary thromboprophylaxis (up to 45 days), prolonged hospital discharge (up to 6 weeks), and in those managed as outpatients could have a better risk-benefit ratio in SARS-CoV-2 infection (Nalbandian et al., 2021). Anticoagulation agents such as direct oral anticoagulants and low-molecular-weight heparin are preferred in post-COVID-19 infection (Barnes et al., 2020). Similar to triggered VTE, anticoagulation drugs are prescribed for those with imaging-confirmed venous thromboembolism (up to 3 months) (Bai et al., 2020; Moores et al., 2020).

8.3. Cardiovascular conditions and their management after COVID-19

A Chinese study reported that 20% of COVID-19 recovered patients at 60 days' follow-up documented chest pain while 9% and 5% of COVID-19 recovered patients showed continuing palpitations and chest pain respectively at 6 months follow-up (Carvalho-Schneider et al., 2021; Nalbandian et al., 2021). In those with cardiovascular problems after an acute infection or recurrent heart symptoms, assessment with electrocardiogram and echocardiogram for serial clinical and imaging at 4–12 weeks can be considered (Desai et al., 2021; Peter M. George et al., 2020). Abstaining from competitive activities or physical exercise up to 6 months before myocarditis is resolved by cardiac magnetic resonance imaging or troponin normalization. It is also recommended for sportsperson with COVID-19-related cardiovascular complications (Hendren et al., 2020; Maron et al., 2015). In persons with stable cardiovascular disease, renin-angiotensin-aldosterone system (RAAS) inhibitors are useful and should be sustained, despite initial theoretical worries about the possibility of acute COVID-19 and increased levels of ACE2 with their use (Hendren et al., 2020; Lopes et al., 2021). Instead, abruptly stopping RAAS inhibitors may be dangerous (Lopes et al., 2021). Low-dose beta-blockers can help patients to regulate their heart rates and diminish adrenergic activity (Raj et al., 2009; Vaduganathan et al., 2020). The use of medications in patients like anti-arrhythmic agents (like amiodarone) with fibrotic pulmonary changes following COVID-19 needs special attention (Lopes et al., 2021; Nalbandian et al., 2021; Raj et al., 2009).

8.4. Neuropsychiatric conditions and their management after COVID-19

COVID-19 survivors have documented recurrent malaise, diffuse myalgia, sleep disturbance, and depressive symptoms (Nalbandian et al., 2021; Raj et al., 2009). Migraine-like headaches and late-onset headaches linked to elevated cytokine levels are other COVID-19 post-acute manifestations (Arca and Starling, 2020; Belvis, 2020; Nalbandian et al., 2021). A clinical study reported around 10% of patients, having loss of taste and smell with recurrent headache (Huang et al., 2021; Nalbandian et al., 2021). Nearly 30–40% of patients reported clinically severe depression and anxiety (Nalbandian et al., 2021). For neuropsychologic conditions such as migraine, standard treatments may be used with the consultation of a physician (Do et al., 2019). In patients with cognitive dysfunction, a neuropsychological assessment should be considered in the post-acute disease environment (Nalbandian et al., 2021).

8.5. Renal conditions and their management after COVID-19

Extreme acute kidney injury (AKI) affects 5–6% of all hospitalized patients with up to 30% of critically COVID-19 patients which demanding renal replacement therapy (RRT), particularly those with severe infections requiring mechanical ventilation (Robbins-Juarez et al., 2020; Stevens et al., 2020). Although the prevalence of dialysis-dependent AKI at discharge is poor, the degree of renal function improvement is not surfaced. Therefore, COVID-19 recovered patients with persistently compromised renal function in the post-COVID-19 infectious process can benefit from nephrologists in AKI survivor clinics, which has been linked to better outcomes in the past (Gupta et al., 2020; Nalbandian et al., 2021; Stevens et al., 2020).

8.6. Endocrine conditions and their management after COVID-19

Patients without diabetes mellitus have developed diabetic ketoacidosis, weeks to months after the COVID-19 signs have resolved (Satish and Chandrika Antoon, 2021). COVID-19 can also exacerbate autoimmune thyroid diseases, such as Hashimoto’s thyroiditis or Graves’ disease (Ching et al., 2018; Mateu-Salat et al., 2020). In patients with recently diagnosed diabetes mellitus who do not have typical risk factors for type 2 diabetes, serologic tests for type 1 diabetes-related autoantibodies and repeat post-prandial C-peptide analyses should be done at follow-up, while it is appropriate to handle patients with such risk factors as if they had ketosis-prone type 2 diabetes (DiMeglio et al., 2018). Corticosteroids can be used to control hyperthyroidism caused by SARS-CoV-2-related disruptive thyroiditis (Ruggeri et al., 2021).

8.7. Gastrointestinal and hepatobiliary conditions and their management after COVID-19

COVID-19 can change the gut microbiota, favoring opportunistic infectious agents thus reducing beneficial commensals (Donati Zeppa et al., 2020; Zuo et al., 2020). The gut microbiota’s capacity to influence the progression of respiratory infections (gut–lung axis) has previously been recognized in influenza and other respiratory infections (Bradley et al., 2019). Faecalibacterium prausnitzii, a butyrate-producing anaerobe associated with good health, was shown to be inversely linked to disease severity in COVID-19 (Miguez et al., 2013; Nalbandian et al., 2021). Still, clinical research is going on regarding post-COVID-19 effects on gastrointestinal and hepatobiliary systems (Nalbandian et al., 2021).

8.8. Dermatologic conditions and their management after COVID-19

Dermatic manifestations of COVID-19 emerged after (64%) or concurrently with (15%) other post-COVID-19 symptoms in a worldwide sample of 716 individuals with COVID-19, with an estimated delay of 7.9 days in adults from the onset of upper respiratory symptoms to dermatologic outcomes (Freeman et al., 2020; Mirza et al., 2021). In the Chinese trial of recovered COVID-19 patients, only 3% of patients shown skin rash after 6 months (Huang et al., 2021). Hair loss was the most common dermatologic complaint, with about 20% of patients reporting it. Hair loss can be caused by telogen effluvium, which is caused by a viral infection or a stress factor. Still, clinical study is going worldwide regarding the effects of post-COVID-19 on dermatologic conditions (Nalbandian et al., 2021; Sun et al., 2021).

8.9. Secondary infections associated with post-COVID-19 and their management

Mucormycosis, also known as zygomycosis or phymocystis, is a rare and deadly fungal illness that mainly affects people who have a compromised immune system (Chavda and Apostolopoulos, 2021; Valour et al., 2014). The ethioids are the most often affected sinuses, followed by the maxillary sinus (Sharma et al., 2021). According to the study, 8% of secondary bacterial or fungal infections were developed among COVID-19 patients or recovered COVID-19 patients while in the hospital, despite extensive usage of steroids and antibiotics (Rawson et al., 2020). The use of a lot of steroids and broad-spectrum antibiotics to treat COVID-19 might induce or worsen fungal illness (Sharma et al., 2021). In a study of 135 COVID-19 infected patients, White et al. reported a 26.7 percent incidence of invasive fungal infections (White et al., 2021).
COVID-19 following points to be considered: for the newer version of the antiviral drugs against more than 5782 ongoing clinical trials registered on ClinicalTrials.gov, combating a variety of viral infections, including COVID-19 until global herd immunity is achieved - a goal that may take a long time. We will be able to effectively control future occurrences if we have numerous reliable medicines in our COVID-19 toolbox. As per USFDA’s CTAP, Antivirals drugs, steroids, cell and gene therapies, and mAbs are just a few of the therapeutics that could effectively cure COVID-19. More than 300 clinical trials are underway in COVID-19 patients to assess the safety and efficacy of various medication options. A swarm of studies published recently in various scientific journals on COVID-19 genesis, pathology, clinical therapies, and drug discovery, as well as repurposing initiatives, which are serving as beacons of hope that a vaccine and/or successful treatment may be available soon. Because SARS-CoV-2 targets the respiratory tract, the medicines are administered in non-invasive ways. Future cellular therapies may also help with COVID-19 treatment. AlloVir and Baylor College of Medicine are collaborating to develop virus-specific T cells (VSTs), which could help in combating a variety of viral infections, including COVID-19. There are many newer drugs and repurposed drugs being investigated for the COVID-19 treatment since last 2 years. As of December 2021, more than 5782 ongoing clinical trials registered on ClinicalTrials.gov, encompasses 189 vaccine, 1387 drug, and 516 mapped drug names under investigation. For the newer version of the antiviral drugs against COVID-19 following points to be considered:

1) The newer versions of the antiviral should have ease of accessibility in all the affected area. It should be available as the over the counter drug if possible. This will make the treatment option more patient friendly.

2) Currently, majority of the drugs for COVID-19 management are given by IV route which required trained medical professionals for drug delivery. In order to tackle the pandemic situation the newer versions of the antiviral should have preferential route of administration either oral (tablet or capsule) or nasal (intranasal spray) for better patient compliance.

3) The newer versions of the antiviral should have better specificity for the specific viral targets. It is highly desirable that these drugs have sufficient concentration at target side and can easily disrupt the viral replication process. Similarly, viral mutation should also be targeted to get the better efficacy profile as a part of standard treatment.

4) The newer versions of the antiviral should have better safety margin with proved efficacy in the large diverse population range. It can easily be given in the initial phase of the infection that prevent the severity of the COVID-19 with less side effects and speedy recovery of the patient without hospitalization.

To date, only government regulators such as the Food and Drug Administration (FDA) have approved a few medications, with the vast majority still under research. The magnitude of the COVID-19 crisis provides a once-in-a-lifetime chance to acquire data on the efficacy of potential therapeutics. This data sheds light not only on the monitoring of coronavirus pathogens, but also on the recent success of various solutions to identifying candidate therapeutics for an emerging disease.

CRediT authors contribution statement

Debdoot Basu: Writing – original draft, written the first draft of the manuscript. VPC and AM prepared the article plot and critically revised the manuscript. All authors have read the final version of the manuscript and approved the same.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

Fig 3 was prepared using templates from BioRender.com. We are very thankful to Dr. Lalit Vora (Queen's University Belfast, UK) for his support in the figure preparation. All authors want to dedicate this work to L M College of pharmacy as a part of the 75th year celebration of the college.

References

Ader, F., Bouscambert-Duchamp, M., Hîtes, M., Peiffer-Smadja, N., Poissy, J., Belhadi, D., Diallo, A., Le, M.-P., Peytavin, G., Staub, T., Greil, R., Grejd, J., Paiva, Jose-Artur, Costagliola, D., Yazdanpanah, Y., Burdet, C., Mentre, F., Egle, A., Greil, R., Joannidis, M., Lampropelt, B., Aitdodafone, A., Belkhir, L., Fraipont, V., Hîtes, M., Verchez, S., Oulahri, W., Ouédraogo, O., Ouédraogo, O., Sallet, M., Lina, B., Nguemandj, A., Dechanet, A., Delatour, M., Farca, K., Faure, E., Figueiredo, S., Gaborit, B., Gaci, R., Gagneux-Grunson, D., Gallien, S., Garot, D., Geri, G., Gilot, S., Goehringer, F., Gousenn, M., Gourdon, D., Hansmann, Y., Hinschberger, O., Jaureguiberry, S., Jeannin, V., Kerneis, S., Kimmoun, A., Kluchh, J., Lacatir, M., Lacombe, K., Laine, F., Lanoix, J.P., Lanay, O., Laviolle, B., Le Meoin, V., Le Pavec, J., Le Toulou, Y., Le Tourneri, F., Lebeaux, D., Lefever, B., Leroy, S., lescoire, F.X., Lesste, H., Leveau, B., Loubet, P., Makinson, A., Malvy, D., Marquette, C.H., Martin-Bondel, G., Martinot, M., Mayaux, J., Mekontso-Dessap, A., Mezina, F., Mira, J.-P., Molina, J.-M., Monnet, X., Mouton, J., Mouinier, J., Muvriller, B., Muvris-Eupin, M., Naveil, J.-C., Noiri, S., Oulderr, W., Peiffer-Smadja, N., Perpoint, T., Piaoulous, G., Pilimis, B., Pirou, V., Piroth, L., Poissy, J., Pourcher, V., Queon, J.-P., Raffi, F., Reinigier, J., Revest, M., Richard, J.-C., Riu-Poulen, B., Robert, C., Roger, P.-A., Roger, C., Rouveix-Nordon, E., Ruch, Y., Saudain, N., Sayner, N., Semeville, E., Soto, A., Stefanis, F., Taccuard, C., Terzi, N., Textoria, J., Thierry, G., Tinarch, J.-F., Tulema, V., Turnel, J.-M., Valour, F., Wattecup, C., Yazdanpanah, Y., Zerhiv, Y., Berma, M., Reuter, J., Staub, T., Braf, S., Ferreiro Ribeiro, J.-M., Paiva, Jose-Artur, Roncon-Albuquerque, R., Bouscambert-Duchamp, M., Gaymard, A., Le, M.-P., Lina, B., Peytavin, G., Tubiana, S., Couffin-Cadizergues, S., Esperou, H., Belhadi, D., Burdet, C, Costagliola, D., Dechanet, A., Delmas, C., Diallo, A., Fougouer, C., Grejd, J., Mentre, F., Mercier, N., Nore, S., Saillard, J., Velou, P., 2021. Mdssevirplus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infec. Dis. https://doi.org/10.1016/S1473-3099(21)00485-0.

Adesanya, T.M.A., Campbell, C.M., Cheng, L., Ogbonu, P.U., Kahwasi, R., 2021. CI extasy inhibition: targeting multiple systems in COVID-19. J. Clin. Immunol. 41, 729-732. https://doi.org/10.1007/s10875-021-00972-1.
biosurfactants, mannoylerythritol lipids. FEMS Yeast Res. 7, 286–292. https://doi.org/10.1111/j.1567-1364.2006.0014x.}

Morokutti-Kurz, M. D. F., Fagar, I. P., Groote, M., Grasser, A., Auth, J., Schubert, U., Friesch-Grasser, I. 2021. Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro. PLoS One 16, e0227480.

Myall, K. J., Mukherjee, B., Castanheira, A. M., Lam, J. L., Benedetti, G., Mak, S. M., Preston, R., Thillaisundaram, B., Mahon, C. A. 2021. Persistent post-COVID-19 intestinal lung disease. An observational study of corticosteroid treatment. Ann. Am. Thorac. Soc. 18, 799–806. https://doi.org/10.1513/AnnalsATS.202011-1139OC.

Nair, M. S., Huang, Y., Fidock, D. A., Poyarkov, S. J., Wagoner, J., Towlger, M. J., Weathers, P. J. 2021. Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants. J. Ethnopharmacol. 274. https://doi.org/10.1016/j.jep.2021.114016.

Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M. V., McGroder, C., Stevens, J. S., Scordo, W. E., Losso, M. H., Ferniot, I., Pardo, P. E., Rodrigues, E., Rucci, P., Pasquali, J., Fuentes, N. A., Esperatti, M., Speroni, G. A., Nannini, E. C., Matteacci, A., Michelangelo, H. G., Follmann, D., Lane, H. C., Belloso, W. H., Group, P. S. 2021. A randomized trial of convalescent plasma in covid-19 severe pneumonia. N. Engl. J. Med. 385, 619–629. https://doi.org/10.1056/NEJMoa2101851.

Singh, T. U., Parida, S., Lingaraju, M. C., Kesavan, M., Kumar, D., Singh, R. K. 2020. Drug repurposing approach to fight COVID-19. Pharmacol. Rep. 72, 1479–1508. https://doi.org/10.1016/j.pr.2020.04.015-6.

Sma, S. W., Saed, M., Alkhamis, A., Khaled, D., Zou, Y., Youns, D. A., Rajah, M. F., Abdallah, W. H., Hussain, H. N., Niaz, K., Saffar, M. 2021. Inflammation, immunity and potential target therapy of SARS-CoV-2: a total scale analysis review. Food Chem. Toxicol. 150, 112087. https://doi.org/10.1016/j.fct.2021.112087.

Stamatakis, A., Kertesz, J., Leclerc, J. C., Foster, R. 2021. COVID-19 Drug Therapy what’s been updated: Highlights. Elsevier, pp. 25–28.

Stal, M., Kortgen, A., Goossens, F., Coldewey, S. M., Reuten, P., Bauer, M. 2020. Influenza virus against severe COVID-19: a cautionary case series. Crit. Care 24, 1–3. https://doi.org/10.1186/s13054-020-01358-0.

Steven, J. S., King, K. L., Robbins-Juarez, S. Y., Khairallah, P. Toma, K., Verduzco, H. A., Daniel, E. L., Douglas, D., Monea, A. P., Peleg, Y., Starakiewicz, P., Li, M. T., Kim, D. W., Yu, K., Qian, L, Shah, V. H., O'Donnell, M. R., Cummings, M. J., Zucker, J., Natrajan, K., Perotte, A., Tsapeas, D., Krzyzost, K., Dube, G., Siddali, E., Shirazian, S., Nickolas, T. L., Rao, M. K., Barasch, J. M., Valeri, A. M., Radhakrishnan, J., Ghanvi, A. G., Huzin, S. A., Mohan, S. 2020. High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy. PLoS One 15, 1–14. https://doi.org/10.1371/journal.pone.0244131.

Stumback, T. W., Dawson, M. J., Bina, H. K. 2020. Beyond antibodies: the DARPin® drug platform. Bioscience Drugs 34, 423–433. https://doi.org/10.20529/bios-20-00429-8.

Sun, B., Tang, N., Peluso, M. J., Eyre, N. S., Torres, L., Donatelli, J. L., Munter, S. E., Sun, B., Tang, N., Peluso, M. J., Iyer, N. S., Torres, L., Donatelli, J. L., Munter, S. E., 2021. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Clin. Pharmacol. 384, 629. https://doi.org/10.1038/s41577-020-03158-0.

Taylor, P. C., Adams, A. C., Hufford, M. M. de la Torre, I., Winthrop, K., Gottlieb, R. L. 2021. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Immunol. 21. 382–393. https://doi.org/10.1038/s41577-021-00542-x.

Tillet, R. L., Sevinsky, J. R., Hartley, P. D., Kerwin, H., Crawford, N., Gorzalski, A., Tocilizumab for treatment patients with COVID-19: recommended medication for therapy COVID-19. Pharmacol. Rep. 72, 1479–1508. https://doi.org/10.1016/j.pr.2020.04.015-6.

Tillett, R. L., Sevinsky, J. R., Hartley, P. D., Kerwin, H., Crawford, N., Gorzalski, A., Tocilizumab for treatment patients with COVID-19: recommended medication for therapy COVID-19. Pharmacol. Rep. 72, 1479–1508. https://doi.org/10.1016/j.pr.2020.04.015-6.

Wallace, N. M., Rawlings, N. D., Zhang, F., Winkler, A. M., Molyneaux, P. L., West, A. G., 2021. Persistent post-COVID-19 Symptoms: a rapid review to support COVID-19 antimicrobial prescribing. Ann. Am. Thorac. Soc. 18, 799–806. https://doi.org/10.1016/j.jep.2021.114016.

Wang, C., Xia, R., Wu, S., Zhang, W., Wang, T., Wu, X., Wang, B., Liang, Y., Wang, S., Zhang, L., Qu, Y., Wu, J., Wu, Y., Sheng, A., Li, P., Ma, Y., Zhan, J., Shi, L., Zhang, R., Wang, E., Wang, J., Guo, X., Wu, Y., Zhang, X., Li, X., Chen, C., Zhang, J., Zhou, X., Zhang, H., 2021. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action. Naunyn-Schmiedeberg's Arch. Pharmacol. 393, 1153–1156. https://doi.org/10.1007/s00210-021-01679-x.

Wilkinson, A. J., Stone, M. A., Ault, S. A., MacGillivray, J. S., Brown, T., Moulton, S. L., 2020. Influenza virus in COVID-19: a systematic review and meta-analysis. Kidney Int. Rep. 5, 1149–1160. https://doi.org/10.1016/j.ekir.2020.06.013.

Witt, R. M., Avorn, J., 2020. Drug evaluation during the covid-19 pandemic. N. Engl. J. Med. 382, 1653–1659. https://doi.org/10.1056/NEJMoa2031304.

Yancey, M., Vangeel, L., Dejonghe, S., Chaltin, P., Marchand, A., Serebryany, V., Stoycheva, A., Van Overbeek, E., Vangeel, L., Dejonghe, S., Chaltin, P., Marchand, A., Serebryany, V., Stoycheva, A., Van Overbeek, E., 2021. Antiviral drugs for acute infections. In: Powell, K. L., Thomas, E., Cockerill, G. S. 2017. Antiviral drugs for acute infections. Nature doi.org/10.1038/s41591-021-01283-z.

Zhang, X., Yang, B., Gao, L., Han, L., Wang, Y., Li, Y., Chen, C., Li, J., Zhang, H., 2020. Outcomes for patients with COVID-19 and acute kidney injury: a systematic review and meta-analysis. Medicine (Baltim). 99, 4952. https://doi.org/10.1093/med/ztz343.
Vicenti, I., Zazzi, M., Saladini, F., 2021. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert Opin. Ther. Pat. 31, 325–337. https://doi.org/10.1080/13543776.2021.1885056.

Wang, X., Guan, Y., 2021. COVID-19 drug repurposing: a review of computational screening methods, clinical trials, and protein interaction assays. Med. Res. Rev. 41, 5–28. https://doi.org/10.1002/med.21728.

Wang, Yeming, Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., Hu, Y., Luo, G., Wang, K., Lu, Y., Li, H., Wang, S., Ruan, S., Yang, C., Mei, C., Wang, Yi, Ding, D., Wu, F., Tang, X., Ye, X., Ye, Y., Liu, B., Yang, J., Yin, W., Wang, A., Fan, G., Zhou, F., Liu, Z., Gu, X., Xu, J., Shang, L., Zhang, Y., Cao, L., Guo, T., Wan, Y., Qin, H., Jiang, Y., Jaki, T., Hayden, F.G., Horby, P.W., Cao, B., Wang, C. 2020a. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395, 1569–1578. https://doi.org/10.1016/S0140-6736(20)31022-9.

Wang, Yeming, Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., Hu, Y., Luo, G., Wang, K., Lu, Y., Li, H., Wang, S., Ruan, S., Yang, C., Mei, C., Wang, Yi, Ding, D., Wu, F., Tang, X., Ye, X., Ye, Y., Liu, B., Yang, J., Yin, W., Wang, A., Fan, G., Zhou, F., Liu, Z., Gu, X., Xu, J., Shang, L., Zhang, Y., Cao, L., Guo, T., Wan, Y., Qin, H., Jiang, Y., Jaki, T., Hayden, F.G., Horby, P.W., Cao, B., Wang, C. 2020b. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395, 1569–1578. https://doi.org/10.1016/S0140-6736(20)31022-9.

Weinreich, D.M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhide, R., Musser, B.J., Soo, Y., Rofail, D., Im, J., Perry, C., Fan, C., Hosain, R., Mahmood, A., Davis, J.D., Turner, K.C., Hooper, A.T., Hamilton, J.D., Baum, A., Kyratsou, C.A., Kim, Y., Cook, A., Kampman, W., Kohli, A., Sachdeva, Y., Graber, X., Kowal, B., DiCicco, T., Stahl, N., Lipsich, L., Braunstein, N., Herman, G., Yancopoulos, G.D., 2020. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. N. Engl. J. Med. 384, 497–511. https://doi.org/10.1056/NEJMoA2023184.

World Health Organization, 2021a. COVID-19 Weekly Epidemiological Update 22. World Heal. Organ 1–3.

World Health Organization (WHO), 2021b. WHO-COVID-19-global-data.

Zeng, X., Song, X., Ma, T., Pan, X., Zhou, Y., Hou, Y., Zhang, Z., Li, K., Karypis, G., Cheng, F., 2020. Repurpose open data to discover therapeutics for COVID-19 using deep learning. J. Proteome Res. 19, 4624–4636. https://doi.org/10.1021/acs.jproteome.0c00316.

WHO, 2020. Repurposed antiviral drugs for covid-19 — interim WHO solidarity trial results. N. Engl. J. Med. 384, 497–511. https://doi.org/10.1056/NEJMoA2023184.